Benchmark upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.
Separately, Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th.
View Our Latest Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Tesla Stock: What To Expect With Their Delivery Numbers Report
- How to Profit From Growth Investing
- First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock
- 3 Small Caps With Big Return Potential
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
